8-K: Calidi Biotherapeutics Unveils CLD-401 Data at SITC 2025

Calidi Biotherapeutics presented new preclinical data on its lead therapeutic candidate, CLD-401, at the 2025 SITC Annual Meeting, highlighting its RedTail platform's ability to target metastatic tumors.

Summary

• New data on CLD-401, the first therapeutic candidate from the RedTail platform, was presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting.
• CLD-401 is an oncolytic virus designed for systemic delivery, specific replication in tumor cells at metastatic sites, immune priming, and high expression of IL-15 superagonist in the tumor microenvironment (TME).
• Data from syngeneic murine models demonstrate that the RedTail platform protects CLD-401 from immune clearance after systemic administration.
• The platform successfully finds and specifically replicates in tumor cells at metastatic sites.
• It effectively expresses genetic medicines at the tumor site in concentrations comparable to localized dosing, while significantly minimizing systemic exposure.
• Levels of IL-15 superagonist in the TME after systemic administration are comparable to levels seen with intrathecal administration of Anktiva in the bladder.
• IL-15 superagonist levels in serum or organs in these models are several orders of magnitude lower than those expressed in the tumor.
• Calidi believes this represents an unprecedented level of targeted genetic medicine delivery and expression.
• An investor day was held featuring Scientific Advisory Board members Dr. Dimitri Zamarin and Dr. John Wrangle, who discussed the promise and differentiation of CLD-401 and the RedTail platform.

Sentiment

Score: 7

Explanation: The filing presents strong positive preclinical data for a key therapeutic candidate and outlines a clear path to IND submission. The involvement of prominent experts and the strategic partnership pursuit are also positive. However, it's still preclinical, and significant risks related to capital, clinical trial outcomes, and FDA approval are clearly stated.

Positives

• New preclinical data demonstrates the RedTail platform's ability to protect CLD-401 from immune clearance after systemic administration in syngeneic murine models.
• CLD-401 successfully targets and replicates specifically in tumor cells at metastatic sites.
• The platform achieves high local expression of genetic medicines (IL-15 superagonist) in the tumor microenvironment, comparable to localized dosing, while minimizing systemic exposure (several orders of magnitude lower in serum/organs).
• Management believes this represents an unprecedented level of targeted genetic medicine delivery and expression.
• The investor day featured positive endorsements from world-renowned experts, Dr. Dimitri Zamarin and Dr. John Wrangle, on the promise and differentiation of CLD-401 and the RedTail platform.
• The company is actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.

Risks

• Risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• Risk that early results of clinical trials do not necessarily predict final results.
• Risk that one or more clinical outcomes may materially change following more comprehensive review of the data and as more patient data becomes available.
• Risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates.
• Other risks and uncertainties are set forth in the section entitled Risk Factors and Cautionary Note Regarding Forward-Looking Statements in the Company's annual report filed with the SEC on Form 10-K on March 31, 2025.

Future Outlook

Calidi is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug (IND) application by the end of 2026. The company is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform. Forward-looking statements include planned clinical trials and statements relating to the safety and efficacy of Calidi's therapeutic candidates in development.

Management Comments

• "Our latest data demonstrate that in our syngeneic murine models, our RedTail platform is protected from immune clearance after systemic administration and can find and specifically replicate in tumor cells at metastatic sites." Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations.
• "The data also demonstrate that the platform can effectively express genetic medicines at the tumor site in concentrations that are similar to what is achievable with localized dosing while avoiding systemic exposure." Antonio F. Santidrian, PhD.
• "In our syngeneic models, we are demonstrating levels of IL-15 superagonist in the tumor microenvironment after systemic administration that are comparable to levels seen with intrathecal administration of Anktiva in the bladder." Eric Poma, PhD, Chief Executive Officer.
• "The level of IL-15 superagonist in serum or organs in these models is several orders of magnitude lower than what is expressed in the tumor. We believe this represents an unprecedented level of targeted genetic medicine delivery and expression." Eric Poma, PhD.

Industry Context

The presentation of new preclinical data for an oncolytic virus therapy at a major immunotherapy conference (SITC) positions Calidi within the competitive and rapidly evolving field of cancer immunotherapy and gene therapy. The focus on systemic delivery and targeted expression of potent cytokines like IL-15 superagonist addresses key challenges in oncology, aiming to improve efficacy and reduce systemic toxicity compared to traditional approaches. Strategic partnerships are common in biotech to de-risk and accelerate development, indicating Calidi's alignment with industry practices for advancing novel therapies.

Comparison to Industry Standards

• The company highlights that the levels of IL-15 superagonist in the tumor microenvironment after systemic administration are comparable to levels seen with intrathecal administration of Anktiva in the bladder, suggesting a potential advantage in achieving localized therapeutic concentrations via systemic delivery, which is a significant challenge in oncology.
• The claim of "unprecedented level of targeted genetic medicine delivery and expression" implies a potential competitive edge over existing or developing therapies that struggle with systemic exposure and off-target effects.
• The involvement of world-renowned experts like Dr. Dimitri Zamarin (virotherapy) from the Icahn School of Medicine at Mount Sinai and Dr. John Wrangle (IL-15 superagonist clinical work) from the Medical University of South Carolina (MUSC) suggests the platform is being evaluated against high industry standards and clinical relevance.

Stakeholder Impact

• Shareholders: Positive preclinical data and a clear development timeline could increase investor confidence, but risks related to funding and clinical success remain.
• Patients: The development of CLD-401 offers potential new therapeutic options for non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need.
• Employees: Continued progress in the pipeline supports job security and potential growth opportunities within the company.
• Partners: Active pursuit of strategic partnerships indicates potential for collaboration and broader impact within the biopharmaceutical industry.

Next Steps

• Conducting IND-enabling studies for CLD-401.
• Anticipates submitting an Investigational New Drug (IND) application for CLD-401 by the end of 2026.
• Actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.

Key Dates

Recommendation

While the preclinical data for CLD-401 is promising, demonstrating targeted delivery and potent local expression, the therapy is still in early stages (IND-enabling studies). Significant risks remain, including the need for substantial capital to fund future clinical trials and the inherent uncertainties of drug development and regulatory approval. The positive preclinical results warrant continued observation, but the early stage and funding risks suggest a 'hold' rather than a 'buy' or 'sell' at this point, pending further clinical progress and financial clarity.

Keywords

Biotechnology, Oncology, Cancer Therapy, Oncolytic Virus, Genetic Medicine, CLD-401, RedTail Platform, IL-15 Superagonist, SITC, Clinical-Stage, Metastatic Cancer, Immunotherapy